Bristol Myers Squibb Partnership
Transforming oncology through AI-driven precision medicine
Strategic Alliance
Our partnership with Bristol Myers Squibb represents a transformative collaboration in oncology research and precision medicine. Together, we are leveraging AI to accelerate drug discovery, optimize treatment protocols, and improve patient outcomes across multiple cancer types.
This alliance combines Bristol Myers Squibb's world-class clinical expertise and drug development capabilities with SynThera's cutting-edge AI platform and real-world evidence analytics.
Partnership Impact
Core Research Areas
Immuno-Oncology AI
Developing predictive models for immunotherapy response and resistance mechanisms
Precision Medicine
AI-driven biomarker discovery and patient stratification for personalized treatments
Drug Discovery
Accelerating novel compound identification and optimization using machine learning
Clinical Trial Optimization
Enhancing trial design, patient recruitment, and endpoint prediction
Real-World Evidence
Analyzing post-market surveillance data to optimize treatment protocols
Combination Therapy
Identifying optimal drug combinations and dosing regimens through AI
Active Research Programs
AI-Powered Biomarker Discovery for Immunotherapy
Phase II Clinical ValidationUsing multimodal AI to identify novel biomarkers predictive of response to immune checkpoint inhibitors across multiple tumor types.
Precision CAR-T Cell Therapy Optimization
Preclinical DevelopmentDeveloping AI models to predict CAR-T cell therapy efficacy and optimize manufacturing parameters for improved patient outcomes.
Real-World Evidence Platform for Oncology
Data Analysis PhaseLarge-scale analysis of real-world patient data to identify treatment patterns, outcomes, and optimization opportunities.
AI-Guided Combination Therapy Design
Discovery PhaseMachine learning approaches to identify synergistic drug combinations and optimal sequencing for enhanced therapeutic efficacy.
Research Outcomes & Achievements
Clinical Breakthroughs
- •20% improvement in immunotherapy response prediction
- •3 new biomarkers discovered and validated
- •15% reduction in treatment-related adverse events
- •Enhanced patient quality of life scores
Scientific Publications
- •Nature Cancer publications (2)
- •Journal of Clinical Oncology (3)
- •Science Translational Medicine (1)
- •Conference presentations at ASCO (8)
Innovation Pipeline
- •7 patents filed for AI algorithms
- •2 FDA breakthrough therapy designations
- •4 investigational new drug applications
- •Platform technology licensing agreements
AI-Enhanced Clinical Trials
Trial Optimization
Our AI platform is integrated into Bristol Myers Squibb's clinical trials to optimize patient selection, predict treatment responses, and identify early efficacy signals.
- •30% reduction in patient screening time
- •Improved patient stratification accuracy
- •Real-time safety monitoring and alerts
- •Enhanced endpoint prediction capabilities
Digital Biomarkers
Advanced analytics of digital health data, imaging, and molecular profiling to identify novel predictive and prognostic biomarkers for oncology therapeutics.
- •Multi-omics data integration
- •Liquid biopsy analytics
- •Radiomics and imaging biomarkers
- •Patient-reported outcome measures
Future Vision & Roadmap
2025-2026 Objectives
- •Launch AI-powered companion diagnostics
- •Expand to rare cancer indications
- •Integrate with digital therapeutics
- •Develop resistance prediction models
Long-term Impact
- •Transform oncology care delivery
- •Enable truly personalized cancer treatment
- •Accelerate drug development timelines
- •Improve global cancer outcomes